Actively Recruiting
Evaluating Safety and Dosing of EGFRIL13R2 Pool-CAR T Cells Delivered Locoregionally for Recurrent or Progressive High-Grade Gliomas
Led by City of Hope Medical Center · Updated on 2026-10-23
24
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial studies adults with recurrent or progressive high-grade gliomas, a type of brain tumor that has returned or worsened after initial treatment. It evaluates the safety and best dosing of a new treatment called EGFRIL13R2 pool-chimeric antigen receptor CAR T cells, which are immune cells modified in the lab to attack tumor cells. This is a phase 1 dose-escalation trial aimed at understanding side effects and dosing levels for this treatment. Participants first undergo leukapheresis to collect their immune cells, followed by surgery to place a catheter in the brain. The modified CAR T cells are then given directly into the brain through this catheter over 5 minutes on day 1 of each 7-day cycle. Up to 4 cycles are given unless the disease progresses or side effects are unacceptable. Additional cycles or leukapheresis may occur based on doctor and patient discretion. Various procedures including imaging scans and sample collections are performed throughout the study. During the trial, participants have assessments such as echocardiography, PET and MRI scans, and collection of blood, cerebrospinal fluid, and tumor cavity fluid samples. Researchers monitor side effects, disease control, response rates, time to progression, and overall survival for up to 15 years. They also study immune responses, CAR T cell behavior, tumor markers, and other biological factors. Follow-up visits occur at day 30, then every 3 months for the first year, and yearly up to 15 years after the last treatment.
CONDITIONS
Brief Title
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here